department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Aricept · pharmadog

pharmadog
drugs
Aricept

drug

patient view →

Aricept

Marketedupdated 2mo ago

by Eisai Co Ltd

Approved

community read0 votes

indications

investigational

Alzheimer's Disease

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Aricept

generic

donepezil hydrochloride

indication

Dementia Associated With Alzheimer's Disease

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 4, 2026

89 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (23)

Aug 11, 2038formulationUS 10966936
Aug 11, 2038formulationUS 10966936
May 20, 2038formulationUS 10835499
May 20, 2038formulationUS 10835499
Sep 23, 2037formulationUS 11648214
Sep 23, 2037formulationUS 11648214
Jul 26, 2037method-of-use (U-3334)US 10016372
Jul 26, 2037method-of-use (U-3334)US 10016372
Jul 26, 2037formulationUS 10300025
Jul 26, 2037formulationUS 10300025
Jul 26, 2037formulationUS 10307379
Jul 26, 2037formulationUS 10307379
Jul 26, 2037method-of-use (U-3334)US 11103463
Jul 26, 2037method-of-use (U-3334)US 11103463
Jul 26, 2037formulationUS 9993466
Jul 26, 2037formulationUS 9993466
May 26, 2037method-of-use (U-3334)US 11679086
May 26, 2037method-of-use (U-3334)US 11679086
Dec 30, 2036compositionUS 12161767
Dec 30, 2036compositionUS 12161767
Dec 30, 2036method-of-use (U-3334)US 12168075
Dec 30, 2036method-of-use (U-3334)US 12168075
Oct 4, 2026formulationUS 848156589d

Trials studying Aricept

phase3Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Typenot yet recruitingn=720
phase2A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.active not recruitingn=62
phase1Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteerscompletedn=60
—Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's Diseasecompletedn=894